Please note that eDoc will be permanently shut down in the first quarter of 2021!      Home News About Us Contact Contributors Disclaimer Privacy Policy Help FAQ

Home
Search
Quick Search
Advanced
Fulltext
Browse
Collections
Persons
My eDoc
Session History
Login
Name:
Password:
Documentation
Help
Support Wiki
Direct access to
document ID:


          Institute: MPI für Herz- und Lungenforschung (W. G. Kerckhoff Institut)     Collection: Publikationen des W. G. Kerckhoff-Instituts     Display Documents



ID: 559636.0, MPI für Herz- und Lungenforschung (W. G. Kerckhoff Institut) / Publikationen des W. G. Kerckhoff-Instituts
Riociguat for pulmonary hypertension
Authors:Ghofrani, H. A.; Voswinckel, R.; Gall, H.; Schermuly, R.; Weissmann, N.; Seeger, W.; Grimminger, F.
Title of Journal:Future Cardiol
Volume:6
Issue / Number:2
Start Page:155
End Page:66
Audience:Not Specified
Abstract / Description:Pulmonary hypertension (PH) encompasses a group of diseases associated with progressively increasing pulmonary vascular resistance, right heart failure and premature death. Riociguat is a novel, first-in-class oral drug that directly stimulates soluble guanylate cyclase, both independently of the endogenous vasodilator nitric oxide (NO) and in synergy with NO. Single oral doses of riociguat were well tolerated in a Phase I study of healthy volunteers. They had a favorable safety profile, and improved pulmonary hemodynamics and cardiac index to a greater extent than inhaled NO in a proof-of-concept study in patients with moderate-to-severe PH. In a 12-week Phase II trial in patients with chronic thromboembolic PH or pulmonary arterial hypertension, pulmonary hemodynamics and exercise capacity improved following individual dose titration with oral riociguat, which was generally well tolerated. Further trials in PH have been initiated.
Free Keywords:Administration, Oral; Endothelium, Vascular/drug effects; Exercise Tolerance/drug effects/physiology; Guanylate Cyclase/*antagonists & inhibitors; Half-Life; Hemodynamics; Humans; Hypertension, Pulmonary/*drug therapy/physiopathology; Pyrazoles/pharmacokinetics/pharmacology/*therapeutic use; Pyrimidines/pharmacokinetics/pharmacology/*therapeutic use; Vascular Resistance/drug effects
External Publication Status:published
Document Type:Article
Communicated by:N. N.
Affiliations:MPI für physiologische und klinische Forschung
External Affiliations:Department of Internal Medicine, Medical Clinic II/V, University Hospital Giessen and Marburg GmbH, Klinikstrasse 36, 35392 Giessen, Germany. ardeschir.ghofrani@innere.med.uni-giessen.de
Identifiers:ISSN:1744-8298 (Electronic) 1479-6678 (Linking)
URL:http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=..
The scope and number of records on eDoc is subject to the collection policies defined by each institute - see "info" button in the collection browse view.